Emergent BioSolutions (EBS) Tops Q1 EPS by 41c; Guides Q2 Revs Lower

Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $1.53, $0.41 better than the analyst estimate of $1.12. Revenue for the quarter came in at $343 million versus the consensus estimate of $358.47 million.

GUIDANCE:

Emergent BioSolutions sees Q2 2021 revenue of $370-430 million, versus the consensus of $502.3 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• The Buckle (BKE) Tops Q2 EPS by 7c, Beats on Revenue
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance